Focus: Compass Pathways is a UK-based biotech company pioneering psilocybin-assisted therapy for treatment-resistant psychiatric conditions. The company is advancing a focused pipeline in an emerging psychedelic medicine space with multiple Phase 2/3 programs.
Profile data last refreshed 2h ago · AI intelligence enriched 2w ago
Growing — net +7 jobs in 30d
26 jobs added vs 19 removed. Steady team buildout.
Compass Pathways offers high-risk, high-reward opportunity for early-career professionals betting on psychedelic medicine's regulatory viability and commercial potential, contingent on Phase 3 trial success.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Compass Pathways
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Compass Pathways's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 4 crawl cycles